$2.19
+0.13 (+6.31%)
Open$2.03
Previous Close$2.06
Day High$2.26
Day Low$1.96
52W High$26.57
52W Low$10.57
Volume—
Avg Volume80.4K
Market Cap5.58M
P/E Ratio36.21
EPS$0.53
SectorBiotechnology
Analyst Ratings
Strong Buy
9 analysts
Price Target
+800.5% upside
Current
$2.19
$2.19
Target
$19.72
$19.72
$18.07
$19.72 avg
$32.84
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 850.6K | 846.2K | 822.4K |
| Net Income | -189,460 | -228,334 | -201,883 |
| Profit Margin | -22.3% | -27.0% | -24.6% |
| EBITDA | -320,116 | -324,230 | -315,475 |
| Free Cash Flow | -189,627 | -182,540 | -129,892 |
| Rev Growth | +3.9% | -4.1% | +22.7% |
| Debt/Equity | 0.68 | 0.61 | 0.74 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $223.43 | +2.01% | 165.4 | 394.89B |
| AMGN | Amgen Inc | $384.32 | +4.49% | 26.8 | 206.95B |
| GILD | Gilead Sciences Inc | $152.50 | +2.10% | 23.3 | 189.20B |
| VRTX | Vertex Pharmaceuticals Inc | $477.92 | +4.17% | 33.7 | 123.82B |
| REGN | Regeneron Pharmaceuticals | $785.51 | +2.46% | 18.4 | 83.03B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.16 | -0.93% | 995.2 | 43.35B |